Odyssey Therapeutics, Inc.
ODTX
$17.62
$0.301.73%
NASDAQ
| 12/31/2023 | |||||
|---|---|---|---|---|---|
| Revenue | 287.00K | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | 287.00K | ||||
| Cost of Revenue | 25.80M | ||||
| Gross Profit | -25.51M | ||||
| SG&A Expenses | 5.31M | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 31.11M | ||||
| Operating Income | -30.82M | ||||
| Income Before Tax | -28.76M | ||||
| Income Tax Expenses | 96.00K | ||||
| Earnings from Continuing Operations | -28.86M | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -28.86M | ||||
| EBIT | -30.82M | ||||
| EBITDA | -29.59M | ||||
| EPS Basic | -4.93 | ||||
| Normalized Basic EPS | -2.58 | ||||
| EPS Diluted | -4.93 | ||||
| Normalized Diluted EPS | -2.58 | ||||
| Average Basic Shares Outstanding | 6.86M | ||||
| Average Diluted Shares Outstanding | 6.86M | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||